Regulatory perspectives: One academic viewpoint from the United States

The development of new drugs to treat vascular dementia and other conditions in which cognitive impairment is due at least in part to vascular pathology will require future interaction among academic, industry, and government regulatory clinicians and scientists. This article offers the author's perspective on the positive involvement of the Food and Drug Administration in development. of conceptual frameworks and practical approaches to treatment of conditions characterized by vascular burden of the brain.